Heparin Infusion Rate for Pulmonary Embolism
For a 70-kg adult with pulmonary embolism, administer an 80 U/kg IV bolus (5,600 units) followed by an 18 U/kg/hour continuous infusion (1,260 units/hour), then adjust based on aPTT monitoring to maintain 1.5-2.0 times control.
Weight-Based Dosing Protocol
The standard weight-based heparin regimen for PE treatment consists of 1, 2, 3, 4:
- Initial bolus: 80 U/kg IV (maximum 5,000-10,000 units depending on guideline)
- Continuous infusion: 18 U/kg/hour
- For 70-kg patient: 5,600 units bolus, then 1,260 units/hour
This dosing is endorsed by multiple major guidelines including the American College of Chest Physicians (ACCP), European Society of Cardiology (ESC), and American Society of Clinical Oncology 1, 2, 3, 4.
Monitoring and Dose Adjustment
Check aPTT at baseline, then approximately every 4 hours initially until therapeutic range is achieved 3, 5. The target aPTT is 1.5-2.0 times control (approximately 50-70 seconds), which corresponds to anti-Factor Xa levels of 0.3-0.7 IU/mL 1, 3.
aPTT-Based Adjustment Nomogram 3:
- aPTT <35 seconds (<1.2× control): Give 80 U/kg bolus; increase infusion by 4 U/kg/hour
- aPTT 35-45 seconds (1.2-1.5× control): Give 40 U/kg bolus; increase infusion by 2 U/kg/hour
- aPTT 46-70 seconds (1.5-2.3× control): No change (therapeutic range)
- aPTT 71-90 seconds (2.3-3.0× control): Decrease infusion by 2 U/kg/hour
- aPTT >90 seconds (>3.0× control): Stop infusion for 1 hour, then decrease by 3 U/kg/hour
Critical Timing Considerations
Achieving therapeutic aPTT within 24 hours is crucial—patients who reach therapeutic levels faster have significantly lower mortality rates 4. The weight-based nomogram achieves therapeutic anticoagulation more rapidly than fixed-dose regimens, with lower recurrence rates of thromboembolism 4.
Research shows that patients with PE specifically have accelerated heparin clearance compared to those with DVT alone, potentially requiring higher maintenance doses (up to 25 U/kg/hour in some PE patients versus 10-15 U/kg/hour for DVT) 6, 7. This underscores the importance of close aPTT monitoring rather than assuming standard dosing will suffice.
Important Caveats
Supratherapeutic Response Risk
Approximately 42% of patients may initially have supratherapeutic aPTT responses with the 18 U/kg/hour rate 8. Risk factors include:
- Age ≥67 years
- Recent warfarin use (within 7 days)
- Lower body weight
Some evidence suggests a 14 U/kg/hour initial infusion rate may reduce supratherapeutic responses while still achieving therapeutic levels effectively 9, though the 18 U/kg/hour rate remains the guideline standard.
Mandatory Monitoring
- Platelet counts: Monitor daily or every 2-3 days from day 4-14 to screen for heparin-induced thrombocytopenia (HIT), which occurs in up to 5% of patients 2, 5
- Hematocrit and occult blood: Monitor periodically throughout therapy 5
Special Populations
- Severe renal impairment (CrCl <30 mL/min): UFH is preferred over LMWH due to non-renal clearance 2, 10
- Pregnancy: UFH is safe; LMWH also acceptable 3
- Obesity: Standard weight-based dosing applies, though monitoring becomes even more critical
Alternative Considerations
While UFH remains appropriate for PE, LMWH or fondaparinux are generally preferred over UFH for most patients due to more predictable pharmacokinetics, less frequent monitoring, and lower rates of HIT 2, 11. However, UFH is specifically indicated when:
- Primary reperfusion/thrombolysis is being considered (short half-life allows rapid reversal)
- Severe renal impairment is present
- Immediate reversibility may be needed
The FDA-approved dosing for continuous IV infusion is 20,000-40,000 units/24 hours (833-1,667 units/hour), which aligns with the weight-based calculation for most adults 5.